Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.38 · Revenue $19.17M · 2 analysts
Est. EPS $-0.37 · Revenue $22.48M · 1 analysts
Est. EPS $-1.45 · Revenue $76.71M · 3 analysts
Est. EPS $-0.34 · Revenue $23.86M · 1 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $50.5M | +85.9% | +17.5% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-29.6M | -22.2% | -20.9% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +75.3% | +2.0% | -0.4% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -60.5% | +31.8% | -1.2% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -58.7% | +34.3% | -2.8% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-29.6M | -15.5% | +42.8% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -58.6% | +37.9% | +51.4% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 17.6% | +172.4% | +39.1% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 8.87x | +58.5% | -25.6% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $130.1M | +151.1% | -0.5% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -2.12 vs -2.24 | +5.2% | -0.39 vs -0.38 | -3.8% |
| Revenue Surprise | $50.5M vs $50.1M | +0.9% | $18.9M vs $19.2M | -1.2% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Jun 3, 2026 | OBOYLE KEVIN C | director | Common Stock | A | 13,698 | — |
| Jun 3, 2026 | Sidow Kevin | director | Common Stock | A | 13,698 | — |
| Jun 3, 2026 | ROOT JONATHAN D | director | Common Stock | A | 13,698 | — |
| Jun 3, 2026 | YOUNG PHILIP M | director | Common Stock | A | 13,698 | — |
| Mar 3, 2026 | Cordonnier Michael | director, officer: CEO, President | Common Stock | A | 33,264 | $4.35 |
Operator: Ladies and gentlemen, thank you for standing by, and welcome to the Carlsmed First Quarter 2026 Earnings Conference Call. [Operator Instructions] I would now like to turn the conference over to your first speaker today, Stephanie Zhadkevich. Stephanie Zhadkevich: Thank you, operator. Welcome to Carlsmed's First Quarter 2026 Earnings Call. Joining me on today's call are Mike Cordonnier, Chairman and Chief Executive Officer; and Leo Greenstein, Chief Financial Officer. Before we begin, I would like to caution that comments made during this call will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements made on this call that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding the market in which Carlsmed operates, trends, expectations, and demand for Carlsmed's products, expectations with respect to reimbursement, statements about the company's clinical data, surgeon adoption and utilization and Carlsmed's expected financial performance and position in the market. Any forward-looking statements made during this call, including projections for future performance, is based on management's expectations as of today. Carlsmed undertakes no obligation to update these statements, except as required by applicable laws. These statements are neither promises nor guarantees and are subject to known and unknown risks and uncertainties that could cause actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements. For more detailed information, please review the cautionary notes on the earnings materials accompanying today's presentation as well as Carlsmed's filings with the SEC, particularly the risk factors described in Carlsmed's annual report on Form 10-K for the year ended December 31, 2025. I encourage you to review all Carlsmed's filings with the SEC concerning these and other matters. Additionally, during today's call, management will discuss certain non-GAAP financial measures, including adjusted EBITDA. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures is included in today's earnings press release. These filings, along with Carlsmed's press release for the first quarter 2026 results, are available on Carlsmed's website at www.carlsmed.com under the Investors section and include additional information about Carlsmed's financial results. A recording of today's call will also be available on Carlsmed's website by 5:00 p.m. Pacific Time today. Now I would like to turn the call over to Mike to go over Carlsmed's business highlights. Michael Cordonnier: Thank you, Stephanie, and welcome to the team. I would like to welcome everyone on our call today. At Carlsmed, our mission is to improve outcomes and decrease the cost of health care for spine surgery and beyond. To achieve …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Michael John Cordonnier | Co-Founder, Chairman, Chief Executive Officer & President | USD 926,379 | Male | 1977 | Active |
William Durall | Chief Commercial Officer | USD 713,531 | Male | 1964 | Active |
Leonard Greenstein | Chief Financial Officer & Treasurer | USD 601,888 | Male | 1976 | Active |
Niall Patrick Casey | Co-Founder, Chief Intellectual Property Officer & Director | USD 522,489 | Male | 1977 | Active |
Shariq Hussain | Chief Technology Officer | — | Male | — | Active |
Jenifer Kamocsay | Chief Legal Officer & Secretary | — | Female | — | Active |
Jeff Bertolini | Senior Vice President of Operational Excellence | — | Male | — | Active |
Jodi Allen Coe | Senior Vice President of People & Culture | — | Female | — | Active |
Sharon V. Schulzki | Chief Clinical & Market Access Officer | — | Female | 1958 | Active |
Stephanie Zhadkevich | VP & Head of Investor Relations | — | Female | — | Active |
Carlsmed NASDAQ: CARL outlined its strategy for expanding its personalized spine-surgery platform, citing clinical data, reimbursement changes and a planned cervical product launch as potential drivers of growth during a Bank of America small- and mid-cap virtual event.
Carlsmed, Inc. (CARL) Presents at Bank of America SMID Cap Virtual Conference Transcript
Carlsmed, Inc. (CARL) Q2 2026 Earnings Call Transcript
Carlsmed NASDAQ: CARL reported second-quarter 2026 revenue of $18.9 million, up 57% from $12.1 million a year earlier, as growth in its aprevo lumbar platform and contributions from its newer cervical offering lifted procedure volumes.
Carlsmed, Inc. (CARL) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $1.47 per share a year ago.
| Report Date | Employees | Form Type | Filing Date | SEC Filing |
|---|---|---|---|---|
| Dec 31, 2025 | 127 | 10-K | Feb 25, 2026 | View |
